Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics

S.J. Fowler*, J. French*, N.J. Screaton#, J. Foweraker*, A. Condliffe*, C.S. Haworth*, A.R. Exley* and D. Bilton*

ABSTRACT: The aim of the current study was to investigate the prevalence and clinical associations of nontuberculous mycobacteria (NTM) in a well-characterised cohort of patients with adult-onset bronchiectasis.

The sputum of all patients attending a tertiary referral bronchiectasis clinic between April 2002 and August 2003 was examined for mycobacteria as part of an extensive diagnostic work-up. NTM-positive patients subsequently had further sputa examined. A modified bronchiectasis scoring system was applied to all high-resolution computed tomography (HRCT) scans from NTM-positive patients, and a matched cohort without NTM.

Out of 98 patients attending the clinic, 10 had NTM in their sputum on first culture; of those, eight provided multiple positive cultures. Three patients were treated for NTM infection. A higher proportion of NTM-positive than -negative patients were subsequently diagnosed with cystic fibrosis (two out of nine versus two out of 75). On HRCT scoring, more patients in the NTM-positive group had peripheral mucus plugging than in the NTM-negative group.

In the current prospective study of a large cohort of patients with bronchiectasis, 10% cultured positive for nontuberculous mycobacteria in a random clinic sputum sample. Few clinical parameters were helpful in discriminating between groups, except for a higher prevalence of previously undiagnosed cystic fibrosis and of peripheral mucus plugging on high-resolution computed tomography in the nontuberculous mycobacteria group.

KEYWORDS: Bronchiectasis, nontuberculous mycobacteria

Nontuberculous mycobacteria (NTM), also known as opportunistic, environmental or atypical mycobacteria, are ubiquitous in the environment and have been isolated from soil, tap water, dust and clinical laboratories [1]. Guidance has been produced for the diagnosis and treatment of NTM infection [1, 2], which requires satisfaction of clinical, microbiological and radiological criteria. In pre-existing lung disease, especially where there may be frequent exacerbations, such as in bronchiectasis, achieving a definition of clinical and radiological criteria specific for NTM infection is difficult. In such patients, radiographical criteria favouring a diagnosis of NTM infection include pleural disease, pneumonic changes, cavitating nodules, tree-in-bud (TIB) changes away from the main sites of bronchiectasis, and mosaic perfusion [3].

While there is little published information on the prevalence and significance of NTM in bronchiectasis, there are data in cystic fibrosis (CF), where NTM have been cultured from the sputum of 4–24% of screened patients [4, 5]. In a large multicentre study from the USA, culture-positive patients were older, had better lung function and were more likely to be colonised with Staphylococcus aureus, but not with Pseudomonas aeruginosa [5]. These findings had not been reflected in an earlier UK study, in which NTM-positive sputum cultures were associated only with increased requirement for intravenous antibiotics [4]. Further analysis of the cohort from the USA found that lung-function decline was no different in patients with multiple NTM-positive sputum cultures versus those with one or no positive cultures, but that NTM-positive patients did have more characteristic features on high-resolution computed tomography (HRCT) [6].

The current authors therefore prospectively investigated a cohort of patients with adult-onset
bronchiectasis to determine the prevalence of NTM in this group. It is the current authors’ practice to screen all patients for NTM on referral to their tertiary referral bronchiectasis clinic. Clinical indices were also compared with those of bronchiectasis patients who did not grow NTM over that time, to discover whether there was any association with disease severity, antibiotic usage, radiographical changes or microbiology.

METHODS

Subjects
Consecutive patients attending the Papworth Hospital Lung Defence Clinic (Cambridge, UK) between April 2002 and August 2003 were enrolled in the current prospective study. All subjects had a clinical diagnosis of bronchiectasis, confirmed by HRCT. Patients’ full history was taken and a clinical examination performed, with selected tests to further elucidate the cause of the bronchiectasis. Investigations included: α1-antitrypsin levels; CF genetics and subsequent sweat-testing if positive; immunoglobulin levels (including specific antibody responses); microscopic examination of the nasal cilia; and fibroepithelial bronchoscopy. These investigations were performed according to methodologies previously described [7].

Measurements
As part of the current authors’ routine clinical practice, sputum was collected for microscopy and bacterial culture at every clinic visit. Colonisation was defined when the same organism was cultured from sputum on at least two occasions separated by 3 months within 1 yr. At the initial visit, sputum was also sent for mycobacterial culture. This was repeated at subsequent visits in those patients who had grown NTM on first culture. As this was the current authors’ routine clinical practice, neither approval from the Research Ethics Committee nor written patient consent were sought. All patients were further characterised using spirometry, in accordance with American Thoracic Society (ATS) guidelines [8].

Sputum processing
Sputum was stained directly for acid-fast bacilli and decontaminated in sodium hydroxide (2% final concentration). It was cultured by an automated liquid method using the Mycobacteria Growth Indicator Tubes (MGIT) system (Becton Dickinson, Sparks, MD, USA) and on solid media (Lowenstein Jensen (LJ) slopes) [9]. MGIT tubes were incubated for 42 days and LJ slopes for 8 weeks. Mycobacteria were identified in a central reference laboratory using standard methods [10]. After one Mycobacterium sp. was identified from an individual patient, at least two repeat specimens were sent for both culture and identification.

HRCT scan protocol and scoring
Thin (1-mm) collimation computed tomography (CT) images were obtained at 10-mm intervals from lung apices to bases during suspended full inspiration in the supine position. Images were reconstructed using a high spatial frequency reconstruction algorithm and displayed on lung parenchymal window settings (level: -700 Hounsfld units (HU); width: 1200 HU). HRCT images were scored for the severity and extent of bronchiectasis and airways disease using a modified system by Bhalla et al. [11]. Given the good interobserver agreement for the CT features of bronchiectasis previously published [12–14], CTs were evaluated by a single experienced cardiothoracic radiologist.

The extent and severity of bronchiectasis and CT features of airways disease were evaluated at a lobar level, with the lingula considered as a separate lobe. The presence of bronchiectasis was defined using established criteria [15, 16]. The severity of bronchial dilatation (0: normal; 1: 1–2 × diameter of adjacent artery; 2: 2–3 × diameter of adjacent artery; 3: >3 × diameter of adjacent artery), and of bronchial wall thickening (0: normal; 1: <0.5 × diameter of adjacent artery; 2: 0.5–1 × diameter of adjacent artery; 3: >1 × diameter of adjacent artery) was scored for each lobe using previously described criteria [14, 17]. The extent of bronchiectasis [11], mucus plugging [18], sacculations/abscesses [11], mosaic perfusion [18] and collapse or consolidation were assessed on a lobar basis and the number of segments involved recorded. The extent of TIB opacity was scored according to the proportion of lung involved (0: absent; 1: <25%; 2: 25–50%; 3: >50%). The distribution of bronchiectasis and mucus plugging was described for each case as central (central 50%), peripheral (outer 50%) or mixed.

Total lung scores for each abnormality were defined as the mean score from all lobes in the cases of severity of bronchial dilatation, bronchial wall thickening and TIB opacity and by the total number of involved segments (0: none; 1: 1–5 segments; 2: 6–9 segments; 3: >9 segments) for the extent of bronchiectasis [11], mucus plugging [18], sacculations/abscesses [11] and mosaic perfusion [18]. The severity of collapse or consolidation was also scored according to the total number of involved segments (0: normal; 1: 1–3 segments; 2: 4–6 segments; 3: >6 segments). A combined total lung score (0–24) for all CT features was derived by summing the scores for the individual CT features.

HRCT scans were scored as described above for all NTM-positive patients. For each patient, CT scans from two matched NTM-negative patients were also scored. Cases were matched by forced expiratory volume in one second (FEV1), and for the presence of P. aeruginosa in sputum where appropriate. A mean score was then calculated for each NTM-negative pair.

Statistical analysis
Patients were divided into two groups, defined as NTM-positive (those culturing an NTM at first visit), or NTM-negative. These groups were compared using the Chi-squared test for clinical characteristics including number colonised with P. aeruginosa, number and on long-term (daily) antibiotics, number with mutations of the CF transmembrane regulator (CFTR) and CT features. Group mean spirometric values and age were normally distributed and compared using the unpaired t-test. CT scores (total and by section) were not normally distributed. Group means were compared by the Mann–Whitney U-test, and pairs (i.e. each NTM-positive case and the mean of its two matched NTM-negative controls) by the Wilcoxon signed ranks test.
RESULTS

A total of 98 patients (66 females) were investigated, with mean ± SEM age 59.3 ± 1.3 yrs, FEV1 63.5 ± 2.3% predicted, and forced vital capacity (FVC) 85.8 ± 1.9% pred. Of these, 10 grew NTM on first sputum culture; none were smear-positive. These patients were followed up over median (range) 58 (16–88) weeks, and are summarised in table 1.

Patient characteristics of the NTM-positive and -negative groups are shown in table 2. There was no difference between groups in terms of age, sex, spirometry, or numbers with CFTR mutations, culturing groups in terms of age, sex, spirometry, or numbers with CFTR mutations, and after NTM was first cultured, either in the NTM-positive group as a whole, or in the three patients who were subsequently treated.

Trends in FEV1 before and after first positive NTM culture for the NTM-positive group are shown in figure 2. There was no significant difference in FEV1 before and after NTM was first cultured, either in the NTM-positive group as a whole, or in the three patients who were subsequently treated.

CT scores for the NTM-positive group versus the matched cohort are shown in table 4. There were no significant differences in individual or total scores either when analysed as group means (i.e. 10 NTM-positive versus 20 NTM-negative patients) or pairwise (i.e. 10 pairs of NTM-positive versus the average of the two matched NTM-negative patients’ scores). The NTM-positive group did include more individuals with peripheral mucus plugging than the NTM-negative group.

patients tested for both CFTR gene mutations and, if positive, by subsequent sweat test, a higher proportion of NTM-positive than -negative patients had a diagnosis of CF (two out of nine versus two out of 75; p<0.01).

TABLE 1 Clinical characteristics of the 10 subjects sputum culture-positive for nontuberculous mycobacteria (NTM)

| Subject | Age yrs | NTM cultured | FEV1 %pred | Aetiology | Long-term antibiotics | Other microorganisms cultured |
|---------|---------|---------------|------------|-----------|----------------------|-------------------------------|
| 1       | 70      | Environmental scotochromagen × 1 | 80         | Inhalation injury | Nebulised colomycin | P. aeruginosa |
|         |         | Negative × 12 |            |           |                      |                               |
| 2       | 52      | M. fortuitum × 3 | 70         | Rheumatoid-associated | Nebulised colomycin | P. aeruginosa |
|         |         | Negative × 7   |            |           | Oral doxycycline     |                               |
| 3       | 59      | M. fortuitum × 1 | 57         | CF        | Nebulised colomycin | P. aeruginosa |
|         |         | Negative × 9   |            |           |                      |                               |
| 4       | 64      | M. fortuitum × 2 | 76         | Idiopathic |                      | P. aeruginosa |
|         |         | M. xenopi × 1  |            |           |                      |                               |
| 5       | 56      | M. malmoense × 2 | 68         | Post-infective | Oral doxycycline | H. influenzae |
|         |         | Environmental scotochromagen × 1 | |           |                      | S. aureus |
|         |         | Negative × 9 |            |           |                      | M. catarrhals |
| 6       | 53      | M. xenopi × 1  | 35         | Post-infective | Oral amoxicillin | P. aeruginosa |
|         |         | M. chelonae × 1 |            |           |                      | M. catarrhals |
| 7#      | 48      | M. xenopi × 3  | 11         | Idiopathic |                      | S. pneumoniae |
|         |         | Negative × 6 |            |           |                      | P. aeruginosa |
| 8#      | 49      | M. avium intracellulare × 3 | 56         | ABPA | Nebulised colomycin | P. aeruginosa |
|         |         | M. simiae × 1 |            |           |                      |                               |
| 9#      | 61      | M. avium intracellulare × 2 | 38         | CF | Nebulised colomycin | P. aeruginosa |
|         |         | M. spp. × 3 |            |           |                      |                               |
|         |         | M. terrae × 1 |            |           |                      |                               |
| 10      | 82      | M. avium intracellulare × 2 | 108        | Idiopathic | Oral amoxicillin | P. aeruginosa |
|         |         | Negative × 2 |            |           |                      | Coliform |

FEV1: forced expiratory volume in one second; % pred: percentage of predicted value; P. aeruginosa: Pseudomonas aeruginosa; M. fortuitum: Mycobacterium fortuitum; H. influenzae: Haemophilus influenzae; S. pneumoniae: Streptococcus pneumoniae; S. aureus: Staphylococcus aureus; CF: cystic fibrosis; M. xenopi: Mycobacterium xenopi; M. malmoense: Mycobacterium malmoense; M. catarrhals: Moraxella catarrhals; M. chelonae: Mycobacterium chelonae; M. avium intracellulare: Mycobacterium avium intracellulare; ABPA: allergic bronchopulmonary aspergillosis; M. simiae: Mycobacterium simiae; M. terrae: Mycobacterium terrae. #: patient treated for NTM infection.

TABLE 2

| Subject | NTM-Positive | NTM-Negative | FEV1 %pred | Aetiology | Long-term antibiotics | Other microorganisms cultured |
|---------|--------------|--------------|------------|-----------|----------------------|-------------------------------|
| 1       | Yes          | No           | 80         | Inhalation injury | Nebulised colomycin | P. aeruginosa |
| 2       | Yes          | No           | 70         | Rheumatoid-associated | Nebulised colomycin | P. aeruginosa |
|         |              |              | Oral doxycycline |                      |                      |                               |
| 3       | Yes          | No           | 57         | CF        | Nebulised colomycin | P. aeruginosa |
|         |              |              |                      |                      |                      |                               |
| 4       | Yes          | No           | 76         | Idiopathic |                      | P. aeruginosa |
|         |              |              |                      |                      |                      |                               |
| 5       | Yes          | No           | 68         | Post-infective | Oral doxycycline | H. influenzae |
|         |              |              |                      |                      |                      | S. aureus |
|         |              |              |                      |                      |                      | M. catarrhals |
| 6       | Yes          | No           | 35         | Post-infective | Oral amoxicillin | P. aeruginosa |
|         |              |              |                      |                      |                      | M. catarrhals |
| 7#      | Yes          | No           | 11         | Idiopathic |                      | S. pneumoniae |
|         |              |              |                      |                      |                      | P. aeruginosa |
| 8#      | Yes          | No           | 56         | ABPA | Nebulised colomycin | P. aeruginosa |
|         |              |              |                      |                      |                      |                               |
| 9#      | Yes          | No           | 38         | CF | Nebulised colomycin | P. aeruginosa |
|         |              |              |                      |                      |                      |                               |
| 10      | Yes          | No           | 108        | Idiopathic | Oral amoxicillin | P. aeruginosa |
|         |              |              |                      |                      |                      | Coliform |

FEV1: forced expiratory volume in one second; % pred: percentage of predicted value; P. aeruginosa: Pseudomonas aeruginosa; M. fortuitum: Mycobacterium fortuitum; H. influenzae: Haemophilus influenzae; S. pneumoniae: Streptococcus pneumoniae; S. aureus: Staphylococcus aureus; CF: cystic fibrosis; M. xenopi: Mycobacterium xenopi; M. malmoense: Mycobacterium malmoense; M. catarrhals: Moraxella catarrhals; M. chelonae: Mycobacterium chelonae; M. avium intracellulare: Mycobacterium avium intracellulare; ABPA: allergic bronchopulmonary aspergillosis; M. simiae: Mycobacterium simiae; M. terrae: Mycobacterium terrae. #: patient treated for NTM infection.
Patient characteristics for patients with and without nontuberculous mycobacteria (NTM) cultured from their sputum during the study period

|                          | NTM-positive | NTM-negative |
|--------------------------|--------------|--------------|
| Patients                 | 10           | 88           |
| Age yrs                  | 59.4±3.3     | 59.9±1.4     |
| Male                     | 4            | 28           |
| FEV1 % pred              | 59.9±8.6     | 63.9±2.3     |
| FVC % pred               | 86.0±6.9     | 85.8±2.0     |
| CFTR mutations           |              |              |
| 2×ΔF508 het              | 2×ΔF508 het  |
| 7× none                  | 2× R117 het  |
| 1× not known             | 73× none     |
| 11× not known            |              |
| Colonisation             |              |              |
| P. aeruginosa            | 6            | 41           |
| H. influenzae            | 0            | 4            |
| S. aureus                | 0            | 2            |
| Long-term antibiotics    |              |              |
| Colomycin (nebulised)    | 5            | 20           |
| Gentamicin (nebulised)   | 0            | 3            |
| Amoxicillin (oral)       | 2            | 3±1 nebulised|
| Azithromycin (oral)*     | 0            | 1            |
| Ciprofloxacin (oral)*    | 0            | 1            |
| Clarithromycin (oral)*   | 0            | 4            |
| Doxycycline (oral)*      | 2            | 11           |
| Metronidazole (oral)     | 0            | 1            |
| Fluorchloxacin (oral)    | 0            | 1            |
| Trimethoprim (oral)      | 0            | 1            |
| None                     | 2            | 43           |

Data are presented as n or mean±SEM. FEV1: forced expiratory volume in one second; % pred: percentage of predicted value; FVC: forced vital capacity; CFTR: cystic fibrosis transmembrane regulator; P. aeruginosa: Pseudomonas aeruginosa; H. influenzae: Haemophilus influenzae; S. aureus: Staphylococcus aureus; het: heterozygous. *: antibiotic can have antimycobacterial activity. Two NTM-negative patients were taking long-term colomycin and azithromycin and one was taking long-term colomycin and doxycycline. One NTM-positive patient was taking long-term colomycin and doxycycline.

(nine out of 10 versus five out of 20; p<0.001). An example of a CT image demonstrating peripheral mucous plugging is shown in figure 3.

When the data were re-analysed, excluding the two patients in the NTM-positive group who cultured NTM only on the first occasion, members of the NTM-positive group had more segments affected by mucus plugging than members of the NTM-negative group (p=0.019 as group means; 0.026 pairwise). Otherwise, the results were unaffected (data not shown).

**DISCUSSION**

The current authors cultured NTM from the sputum of 10 patients with bronchiectasis, out of a screened sample of 98. NTM were subsequently re-cultured in sputum from eight of these 10 patients. The prevalence of NTM in patients in whom CF had been definitely excluded was seven (9%) out of 80. In a recent prospective cohort, Wickremasinghe et al. [19] reported multiple isolates in one out of 50 screened patients with non-CF bronchiectasis and a further single isolate in one patient. Several groups have reported the prevalence of NTM infection in patients with CF, with results ranging from 2–4% in the UK [4, 20], and 6–24% in the USA [5, 21, 22]. It is also worth noting that all of the current authors’ NTM culture-positive specimens were smear-negative. This compares with ~25% of culture-positives that were smear-positive in the CF-bronchiectasis study by Olivier et al. [5]. The clinical relevance of this is not clear, but it demonstrates that the mycobacterial load in the current authors’ patients was low.

The patients in the current study were seen in a tertiary referral bronchiectasis clinic and, as such, may have features of more

---

**FIGURE 1.** Cause of bronchiectasis in patients positive (Ⅲ) and negative (Ⅲ) for nontuberculous mycobacteria (NTM). ABPA: allergic bronchopulmonary aspergillosis; CF: cystic fibrosis; RA: rheumatoid associated; TB: tuberculosis; GORD: gastro-oesophageal reflux disease; IBD: inflammatory bowel disease. *: p<0.01 NTM positive versus NTM negative.

**TABLE 3** Cause of bronchiectasis

| Diagnosis                        | NTM-positive | NTM-negative |
|----------------------------------|--------------|--------------|
| Idiopathic                       | 35 (40)      | 3 (30)       |
| Immune deficiency                | 16 (18)      | 0 (0)        |
| Allergic bronchopulmonary        | 7 (8)        | 1 (10)       |
| aspergillosis                    |              |              |
| Cystic fibrosis                  | 2 (2)        | 2 (20)       |
| Rheumatoid associated            | 2 (2)        | 1 (10)       |
| Post-tuberculous                 | 5 (6)        | 0 (0)        |
| Gastro-oesophageal reflux        | 2 (2)        | 0 (0)        |
| Post-infective                   | 9 (10)       | 2 (20)       |
| Inflammatory bowel disease       | 4 (5)        | 0 (0)        |
| Pink disease                     | 2 (2)        | 0 (0)        |
| Other                            | 4 (5)        | 1 (10)       |

Data are presented as n (%). NTM: nontuberculous mycobacteria. **: p<0.01 NTM-positive versus NTM-negative.
severe bronchiectasis than is typical for the UK, in terms of recurrent infections, immune deficiencies or symptoms, although this is not apparent from the lung-function data; patients in the current study had a mean FEV1 of 64% pred and FVC of 86% pred. There were no significant differences between NTM-positive and -negative groups in terms of age, sex, spirometry, coexistent sputum bacteriology or use of long-term antibiotics. In CF, TORRENS et al. [4] noted that NTM-positive NTM-negative p-value Patients 10 20 0.76 Age yrs 59 58 0.76 FEV1 % pred 60 61 0.93 Colonised with P. aeruginosa 6 12 ≤ 1 CT scores out of three Consolidation/collapse 0.3 0.3 0.98 Bronchial dilatation 1.3 1.4 0.78 Bronchial wall thickening 0.7 0.8 0.78 Sacculations/abscesses 0.7 0.6 0.98 Mosaic perfusion 1.3 1.6 0.45 Segments affected 2.6 2.5 0.95 Tree-in-bud 0.4 0.6 0.25 Mucus plugging 0.4 0.9 0.12 Total CT score out of 24 8.6 7.6 0.45 CT features Axial distribution 2c, 3m, 5p 12m, 8p ≤ 0.1 Mucus plugging 1a, 9p 15a, 5p ≤ 0.001

Data are presented as n or mean. FEV1: forced expiratory volume in one second; % pred: percentage of predicted value; P. aeruginosa: Pseudomonas aeruginosa; c: central; m: mixed; p: peripheral; a: absent.
that could not be explained by factors other than NTM infection. The third patient (No. 7) was under consideration for lung transplant for bronchiectasis and the transplant team had recommended an attempt be made to eradicate the NTM. ATS microbiological criteria for NTM infection [1] require that three separate sputa test positive for NTM, although the time between sample collections is not specified. Two out of the three (patients 7 and 8) therefore clearly met ATS microbiological criteria for NTM infection. It is not clear from the ATS statement, although it seems sensible, that the three NTM should be of the same species. This is relevant to the third case (patient No. 9), where Mycobacterium avium intracellulare was cultured on two occasions only, but three further sputa grew NTM that could not be further identified. As the ATS radiographical criteria for diagnosis include “multifocal bronchiectasis” as one defining characteristic, and all the patients in the current study had known bronchiectasis, this criterion becomes largely redundant in this population.

On HRCT, more NTM-positive patients than their matched controls had peripheral mucus plugging. Furthermore, when the two subjects who cultured NTM on only one occasion were excluded, the NTM-positive group scored higher than the NTM-negative group for the component of the CT scoring system that assessed the extent of mucus plugging. Otherwise, no difference was seen in the validated CT score in terms of either individual features or overall score. Even in the two patients with a clinical deterioration and multiple NTM positive cultures (patients 8 and 9), there were no unique features when compared with the other 28 CT scores. In CF NTM-positive patients, Torrens et al. [4] also found no differences in Northern chest radiograph scores. This reinforces the view that, in pre-existing structural lung disease, it is difficult to define features with sufficient specificity to aid in the diagnosis of NTM infection.

It is notable that even in patients with multiple NTM-positive sputum cultures, 58 (74%) out of 78 samples were negative. The current authors would therefore support the recommendation that a minimum of three sputum samples should be collected from a patient suspected of being infected with NTM, to minimise the risk of a false-negative result. Indeed it is likely that a proportion of the current NTM-negative group would in fact have cultured NTM subsequently had their sputum been screened for NTM throughout the study period.

There are geographical variations in both the prevalence and causative organisms of NTM infection in CF, and it is very likely that these regional and national differences apply in non-CF bronchiectasis. A recent study by Wickremasinghe et al. [19], based at the Royal Brompton Hospital (London, UK), reported that one patient out of 50 screened met ATS microbiological criteria for NTM infection, and one more tested positive on a single isolate. While the former prevalence (2%) is similar to the present study (3%; patients 2, 7 and 8), many more patients in the current study cultured NTM on more than one occasion, but for various reasons did not fulfil the criteria for infection (patients 4, 5, 6, 9 and 10). This latter difference is difficult to explain, although it may be due partly to geographical variability. It would be very interesting to know the prevalence of NTM in patients with bronchiectasis in other parts of the UK and internationally. Furthermore, NTM can be difficult to culture, especially in the presence of other colonising organisms, so regional differences in technique could account for a degree of variability.

In conclusion, the current authors have reported a 10% prevalence of nontuberculous mycobacteria (3% meeting American Thoracic Society microbiological criteria for infection) in the sputum of screened patients with bronchiectasis in a specialist clinic. No clinical features were identified that were specifically associated with nontuberculous mycobacteria isolation, except for the diagnosis of cystic fibrosis, which warrants further investigation. Previously reported radiographic hallmarks of nontuberculous mycobacterial infection in bronchiectasis [3] did not appear to identify infected individuals in the current population, although the presence of peripheral mucus plugging had 90% sensitivity and 75% specificity for the isolation of nontuberculous mycobacteria. Large prospective studies are required to provide further information to assist diagnosis and management in this difficult area. It would also be interesting to know whether the marked geographical difference in nontuberculous mycobacterial prevalence seen in cystic fibrosis is also evident in non-cystic fibrosis bronchiectasis. In both cases, standardisation of microbiological assays is essential.

ACKNOWLEDGEMENTS
The authors would like to thank F. Cafferty for statistical advice.

REFERENCES
1 American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: Suppl. 1, S1–S25.
2 Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunistic mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000; 55: 210–218.
3 Erasmus JJ, McAdams HP, Farrell MA, Patz EF Jr. Pulmonary nontuberculous mycobacterial infection: radiologic manifestations. Radiographics 1999; 19: 1487–1505.
4 Torrens JK, Dawkins P, Conway SP, Moya E. Nontuberculous mycobacteria in cystic fibrosis. Thorax 1998; 53: 182–185.
5 Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 828–834.
6 Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167: 835–840.
7 Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277–1284.
8 American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107–1136.
9 Leitritz L, Schubert S, Bucherl B, Masch A, Heesemann J, Roggenkamp A. Evaluation of BACTEC MGIT 960 and
BACTEC 460TB systems for recovery of mycobacteria from clinical specimens of a university hospital with low incidence of tuberculosis. J Clin Microbiol 2001; 39: 3764–3767.

10 Gangadharam PR. Microbiology of nontuberculosis mycobacteria. Semin Respir Infect 1996; 11: 231–243.

11 Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991; 179: 783–788.

12 Diederich S, Jurriaans E, Flower CD. Interobserver variation in the diagnosis of bronchiectasis on high-resolution computed tomography. Eur Radiol 1996; 6: 801–806.

13 Grenier P, Mourey-Gerosa I, Benali K, et al. Abnormalities of the airways and lung parenchyma in asthmatics: CT observations in 50 patients and inter- and intraobserver variability. Eur Radiol 1996; 6: 199–206.

14 Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165: 261–267.

15 McGuinness G, Naidich DP. Bronchiectasis: CT/clinical correlations. Semin Ultrasound CT MR 1995; 16: 395–419.

16 Grenier P, Cordeau MP, Beigelman C. High-resolution computed tomography of the airways. J Thorac Imaging 1993; 8: 213–229.

17 Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol 1997; 169: 375–380.

18 Helbich TH, Heinz-Peer G, Eichler I, et al. Cystic fibrosis: CT assessment of lung involvement in children and adults. Radiology 1999; 213: 537–544.

19 Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Nontuberculous mycobacteria in patients with bronchiectasis. Thorax 2005; 60: 1045–1051.

20 Smith MJ, Efthimiou J, Hodson ME, Batten JC. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984; 39: 369–375.

21 Kilby JM, Gilligan PH, Yankaska JR, Highsmith WE Jr, Edwards LJ, Knowles MR. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992; 102: 70–75.

22 Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993; 103: 1096–1099.

23 Bange FC, Kirschner P, Bottger EC. Recovery of mycobacteria from patients with cystic fibrosis. J Clin Microbiol 1999; 37: 3761–3763.